The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00316641
Recruitment Status : Unknown
Verified March 2006 by China Medical University Hospital.
Recruitment status was:  Recruiting
First Posted : April 21, 2006
Last Update Posted : November 7, 2006
Information provided by:
China Medical University Hospital

Brief Summary:
The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients

Condition or disease Intervention/treatment Phase
Hyperlipidemia Drug: Lipid-lowing Tea Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patient aged 20-65 years;either sex
  • Patient diagnosed with hyperlipidemia(fasting levels of TC>=200mg/dL),or TG>=200mg/dL but <400mg/dL,or LDL-C>=130mg/dL)
  • Patient who has signed the informed consent form

Exclusion Criteria:

  • Patient with pregnancy (or child bearing potential),or in lactation
  • Patient with any lipid regulating agents within 4 weeks prior to study period
  • Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
  • Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
  • Patient with liver dysfunction (SGOT or SGPT>2x ULN)
  • Patient with renal insufficiency (serum creatinine>1.3mg/dL)
  • Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00316641

Contact: Chia-I Tsai, V.S 886-4-22052121 ext 5065

China Medical University Hospital Recruiting
Taichung, Taiwan, 404
Contact: Chia-I Tsai, MD    886-4-22052121 ext 5065   
Principal Investigator: Chia-I Tsai, MD         
Sponsors and Collaborators
China Medical University Hospital
Principal Investigator: Chia-I Tsai, V.S China Medical University Hospital,Taichung,Taiwan Identifier: NCT00316641     History of Changes
Other Study ID Numbers: DMR93-IRB-71
First Posted: April 21, 2006    Key Record Dates
Last Update Posted: November 7, 2006
Last Verified: March 2006

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases